CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · General Reference

GemOx

Lymphoma chemotherapeutic regiment

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionJun 10, 2025
Entity authorityQ18031176 ↗
Source-derived summary

GemOx or GEMOX is an acronym for one of the chemotherapy regimens used in the treatment of relapsed or primary refractory non-Hodgkin lymphoma and Hodgkin lymphoma.

When combined with Rituximab it is called R-GemOx, R-GEMOX or GemOx-R, GEMOX-R.

The [R]-GemOx regimen consists of:

Rituximab - anti-CD20 monoclonal antibody that has the ability to kill both normal and malignant B cells;

Gemcitabine - an antimetabolite;

Oxaliplatin - a platinum-based alkylating antineoplastic agent.

Editorial summary

The public source identifies “GemOx” as lymphoma chemotherapeutic regiment. This brief keeps that definition visible, then builds a research path around GemOx, Lymphoma and chemotherapeutic.

Editorial reviewA concise reference frame for defining the subject, testing terminology and identifying the institution closest to the evidence. The current 71-word lead offers orientation but no explicit four-digit date, so chronology should not be assumed. The selected authority fields contribute no independent date. Its value is orientation rather than verdict, with GemOx, Lymphoma and chemotherapeutic providing the first useful test.
Editorial analysis

Why this record matters

A short description can identify a subject without explaining its stakes. For “GemOx”, the useful work is to connect “lymphoma chemotherapeutic regiment” to the records capable of establishing context and consequence.

Evidence profile

The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Jun 10, 2025. The linked authority identifier is Q18031176. None of the 0 selected statements returned an explicit reference.

Critical limits

The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “GemOx”, its source revision and the description used here.
  2. Expand the search: follow GemOx primary sources, GemOx archive and GemOx research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “GemOx”?
  2. What terminology or title could unlock a more precise catalogue search?
  3. Which institution is responsible for the underlying evidence?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “GemOx” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.